Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -31.55% is 16% below its 5-year average of -27.13%, around the middle of its 5-year range (-57.85%–-3.03%).
As of the fiscal period ended Friday, July 31, 2026. 19.41% above its 12-month average of -39.15%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-07-31): -31.55%.
RETURN ON EQUITY (ROE)
-31.55%
RETURN ON EQUITY (ROE) AVG TTM
-39.15%
RETURN ON EQUITY (ROE) AVG 3Y
-27.54%
RETURN ON EQUITY (ROE) AVG 5Y
-27.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+19.41%
CURRENT VS 3Y AVG
-14.59%
CURRENT VS 5Y AVG
-16.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.66%
median of 590 covered companies
CURRENT VS SECTOR MEDIAN
+20.43%
vs the sector median at left
High Tide Inc.
Market Cap
$237.69M
Return on Equity (ROE)
-31.55%
TTM Avg
-39.15%
3Y Avg
-27.54%
5Y Avg
-27.13%
Market Cap
$237.38M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$236.45M
Return on Equity (ROE)
-34.04%
TTM Avg
-95.97%
3Y Avg
-70.55%
5Y Avg
-68.40%
Market Cap
$240.97M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$241.56M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$240.98M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$242.35M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$243.62M
Return on Equity (ROE)
N/A
TTM Avg
-1340.59%
3Y Avg
-55.32%
5Y Avg
-61.68%
Market Cap
$246.67M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| High Tide Inc. (HITI) | $237.69M | -31.55% | -39.15% | -27.54% | -27.13% |
| BioAge Labs Inc. (BIOA)vs › | $237.38M | -25.20% | -25.82% | 5.12% | 5.12% |
| MacroGenics, Inc. (MGNX)vs › | $236.45M | -34.04% | -95.97% | -70.55% | -68.40% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.97M | N/A | -125.28% | -42.20% | -43.41% |
| InflaRx N.V. (IFRX)vs › | $241.56M | -27.27% | -92.43% | -64.95% | -57.80% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.98M | -118.58% | 62.37% | -376.78% | -340.60% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A | 35.05% | 64.68% | -167.54% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A | -1340.59% | -55.32% | -61.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $246.67M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| Biodesix, Inc. (BDSX)vs › | $231.59M | -303.61% | 612.49% | -57.80% | -87.69% |
ROE
-31.6%
ROA
-9.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -31.55% |
| 2026-04-30 | -48.12% |
| 2026-01-31 | -51.41% |
| 2025-10-31 | -57.85% |
| 2025-07-31 | -6.82% |
| 2025-04-30 | -6.78% |
| 2025-01-31 | -4.88% |
| 2024-10-31 | -3.03% |
| 2023-07-31 | -37.37% |
| 2023-04-30 | -38.16% |
| 2023-01-31 | -42.02% |
| 2022-10-31 | -46.41% |
| 2022-07-31 | -12.04% |
| 2022-04-30 | -12.65% |
| 2022-01-31 | -15.61% |
| 2021-10-31 | -23.99% |
| 2021-07-31 | -22.52% |
| 2021-04-30 | -25.90% |
| 2021-01-31 | -38.75% |
| 2020-10-31 | -64.85% |
| 2020-07-31 | -150.58% |
| 2020-04-30 | -366.01% |
| 2020-01-31 | -245.99% |
| 2019-10-31 | -272.03% |
| 2019-07-31 | -59.90% |
| 2019-04-30 | -48.16% |
| 2019-01-31 | -34.16% |
| 2018-10-31 | -19.40% |
| 2018-07-31 | -10.05% |
